Today Agenus also failed to show any meaningful results. One after another, every immunotherapy company fails to show results. When will you guys be convinced that this #$%$ doesn't work? It's all mumbo-jumbo.
David, to cast such a broad brush about Immuno therapy shows that you don't have a clue. I am invested in ONCS which is having incredible success in Melanoma with their DNA immunotherapy along with electroporation. In fact Roche decided to partner with their sister Company Inovio (INO). Wow, I thought Jews were smarter than that. Please forgive the profiling..
So the Polio immunothrapy and small pox etc. does not work too? I guess those investigators should have given up when said it will not work. All the recent tests show is a bad design. That is all.
Vical, Agenus, Dendreon, Celsion, and . .. . . Onty - One would have to believe there are several trial failures in Europe, Japan, and China also. [success, we would of read about it]
Looking at institutional ownership - Acad, 93% - Imuc, 9.76%
ICT-107 is a longshot. A very, very, very long shot.
" you don't want to be the first " - an immunologist.
With the Vical fail, we're up next.
Read this whole message before you reply
I value bears opinions. That said, please givecme your response to the following:
Not all immunotherapy is the same. IMUC's technology is aligned with Dendreon's. Dendreon in fact achieved FDA approva and revs about a third of a billion annually,, so it is not an efficacy failure.
The problem with Dendreon is low margins and logistics. But on a more general note think about how IBM stayed focused on mainframes while microsoft developed PC software. Both companies suceeded with their own business plan. Given that analogy, and the makable case that IMUC will not have Dendreon's problems, you need to better argue the idea that immunotherapy is worthless because big pharma is not interested.
You also should take note that big pharma is not as disinterested as you think, ONTY and AGEN did had big pharma partners for instance.
It's gotta be true, Dr. Yu is stupid...they only let idiots lead Cedar Sinai's Surgical Neuro Oncology group, Brain Tumor Center, and Gamma Knife program! I believe you David Goldberg, you have shown your wisdom so eloquently. Stupid oncologists, big pharma is way smarter....
I dumped my 3000 IMUC today at $2.83 for a loss of about $450. Given the fact that trial results are many months away and given the fact that IMUC's peers are showing bad results I felt that the risk was not worth taking anymore. In fact, I think it's fortunate that IMUC didn't drop more based on AGEN's woes.
"Given the fact that trial results are many months away" LMAO! Awesome...you have it right there but you dont see it. If its true that trial results are many months away, then the people with deadly cancer being treated with ICT 107 are living longer than those untreated. Therfore ICT 107 will have successful trial results if they really are many months away. 2+2= DUH????